This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sagent Pharmaceuticals Announces The Launch Of Docetaxel Injection Concentrate

SCHAUMBURG, Ill., July 31, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Docetaxel Injection Concentrate, an antineoplastic agent, in three preservative-free vial presentations. According to IMS, for the 12 months ending June 2013, the US market for Docetaxel Injection Concentrate approximated $412 million. As with all products in Sagent's portfolio, Docetaxel features Sagent's PreventIV Measures SM packaging and labeling, designed to help reduce medication errors. 

About Docetaxel Injection Concentrate

Docetaxel Injection Concentrate is indicated as a single agent for locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive breast cancer, as a single agent for locally advanced or metastatic non-small cell lung cancer after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated non-small cell lung cancer, with prednisone in androgen independent (hormone refractory) metastatic prostate cancer, with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck cancer.

The package insert, available at www.sagentpharma.com , contains the indications, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.  Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT: INVESTOR CONTACT:
         Jonathon Singer, Sagent
         847-908-1605
         jsinger@sagentpharma.com

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs